SERPINE1 and neoplasm: Type 1 plasminogen inhibitor (PAI-1) is a serine protease catalysing the conversion of plasminogen to plasmin, and is considered an important measure of tumour vascular remodelling and neovascularisation as described in breast carcinoma [2].